According to the nonprofit news outlet NOTUS, at least seven studies cited in the Make America Healthy Again report released ...

While an adverse event reported in Intellia’s gene therapy trial was a “non-concern” for analysts, it follows a handful of ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...

Looking for a biopharma job in New York? Check out the BioSpace list of seven companies hiring life sciences professionals ...

Teos expects to absorb nearly $25 million in one-time costs for severance and termination payments. The biotech had 173 ...

The canceled contract comes as Moderna nears a critical FDA decision for its next-generation COVID-19 vaccine.

In a letter to the Department of Commerce, Novo Nordisk argued that unsanctioned compounded semaglutide, mostly from China, ...

It’s called the peak-end rule. People remember two things most about an experience: the most emotionally intense moment and ...

Nearly a third of employed and almost half of unemployed BioSpace survey respondents are seriously considering leaving the ...

Leerink Partners previews the drugs likely to be subject to the Inflation Reduction Act’s next price negotiations as the ...

A February executive order on pharmaceutical price transparency does nothing to change the incentives that keep costs opaque. But drug companies and other stakeholders would reap the benefits of such ...

InflaRx’s vilobelimab met the bar for futility in a Phase III trial for the rare skin disease pyoderma gangrenosum.